INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL

Projektinformationen

DE-ESCALATE

ID Finanzhilfevereinbarung: 101104574

DOI

10.3030/101104574

EK-Unterschriftsdatum 21 April 2023

Startdatum 1 Juni 2023

Enddatum 31 Mai 2028

Finanziert unter

• Health

Gesamtkosten

€ 7 185 663,75

EU-Beitrag

€ 7 185 663,00

Koordiniert durch

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Belgium

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Documents, reports (5)

Plan for dissemination and exploitation

The plan that will describe project strategy for communication and dissemination

Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster 1

Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster

Policy brief 1

Policy brief formulating recommendations based on the research and innovation strand of the ‘Diagnosis and treatment’ annual cluster meeting

Data Management Plan

The DMP will describe which data/variables are collected, the standards used, how they are processed and stored and how they could be accessed.The preparation of the Data Management Plan will include a common chapter on the ‘Diagnosis and treatment’ cluster. The aim is of the chapter is to address commonalities in data standards, data validation, data protection and foster data exchange.

Initial common work plan for scientific collaboration under the ‘Diagnosis and treatment’ cluster

Other (1)

Project website is online

launch of the project dedicated public website

Veröffentlichungen

Peer reviewed articles (1)

"EORTC 2238 ""De-Escalate"": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors."

Autoren: Grisay G, Turco F, Litiere S, Fournier B, Patrikidou A, Gallardo E, McDermott R, Alanya A, Gillessen S, Tombal B
Veröffentlicht in: Frontiers in oncology, 2024, ISSN 1664-3224
Herausgeber: Frontiers media
DOI: 10.3389/FONC.2024.1391825

Conference proceedings (1)

EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.

Autoren: Guillaume Grisay, Fabio Turco, Anna Patrikidou, Enrique Gallardo Díaz, Raymond S. McDermott, Saskia Litiere, Beatrice Fournier, Silke Gillessen, and Bertrand F. Tombal
Veröffentlicht in: Journal of Clinical Oncology, 2024, ISSN 0732-183X
Herausgeber: American Society of Clinical Oncology
DOI: 10.1200/JCO.2024.42.4_suppl.TPS2